Autologous MSC-NTF Cells May Activate Neuroprotective and Immunomodulatory Pathways from immunomodulatory therapy Watch Video
Preview(s): Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Your browser does not support playing the video.Please download the video!
Description: BrainStorm Cell Therapeutics (NASDAQ: BCLI) is a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases. BrainStorm’s NurOwn® technology platform differentiates a patient’s own bone marrow-derived mesenchymal stem cells to create autologous mesenchymal stem cells secreting neurotrophic-factors (MSC-NTF cells).The autologous MSC-NTF cells are injected into the patient’s cerebrospinal fluid through intrathecal administration where th